138 related articles for article (PubMed ID: 23059902)
1. [Pharmacological profile and clinical efficacy of brimonidine tartrate (AIPHAGAN(®) ophthalmic solution 0.1%)].
Kaneko E; Wada T; Minagawa Y; Inoue Y
Nihon Yakurigaku Zasshi; 2012 Oct; 140(4):177-82. PubMed ID: 23059902
[No Abstract] [Full Text] [Related]
2. Brimonidine (Alphagan): a clinical profile four years after launch.
David R
Eur J Ophthalmol; 2001; 11 Suppl 2():S72-7. PubMed ID: 11592536
[TBL] [Abstract][Full Text] [Related]
3. Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea.
Tong LX; Moore AY
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):567-77. PubMed ID: 25091290
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study.
Krupin T; Liebmann JM; Greenfield DS; Ritch R; Gardiner S;
Am J Ophthalmol; 2011 Apr; 151(4):671-81. PubMed ID: 21257146
[TBL] [Abstract][Full Text] [Related]
5. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment.
Greenfield DS; Liebmann JM; Ritch R
J Glaucoma; 1997 Aug; 6(4):250-8. PubMed ID: 9264305
[TBL] [Abstract][Full Text] [Related]
6. Systemic beta-blocker therapy and brimonidine and timolol.
Coulibaly R
Ophthalmology; 2001 Aug; 108(8):1368. PubMed ID: 11470677
[No Abstract] [Full Text] [Related]
7. Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%.
Katz G; Dubiner H; Samples J; Vold S; Sall K
JAMA Ophthalmol; 2013 Jun; 131(6):724-30. PubMed ID: 23579344
[TBL] [Abstract][Full Text] [Related]
8. Brimonidine--an alpha 2-agonist for glaucoma.
Med Lett Drugs Ther; 1997 Jun; 39(1002):54-5. PubMed ID: 9198727
[No Abstract] [Full Text] [Related]
9. Brinzolamide plus brimonidine for the treatment of glaucoma: an update.
Chew SK; Skalicky SE; Goldberg I
Expert Opin Pharmacother; 2014 Nov; 15(16):2461-71. PubMed ID: 25267543
[TBL] [Abstract][Full Text] [Related]
10. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
LeBlanc RP
Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
[TBL] [Abstract][Full Text] [Related]
11. [Selective α2-agonists in the treatment of glaucoma: pharmacology, efficacy and safety].
Kurysheva NI
Vestn Oftalmol; 2019; 135(2):144-150. PubMed ID: 31215546
[TBL] [Abstract][Full Text] [Related]
12. [The ocular hypotensive effect and safety of 0.2% brimonidine].
Yu M; Li Y; Ge J
Yan Ke Xue Bao; 2001 Dec; 17(4):235-8. PubMed ID: 12567513
[TBL] [Abstract][Full Text] [Related]
13. Brimonidine tartrate-eudragit long-acting nanoparticles: formulation, optimization, in vitro and in vivo evaluation.
Bhagav P; Upadhyay H; Chandran S
AAPS PharmSciTech; 2011 Dec; 12(4):1087-101. PubMed ID: 21879393
[TBL] [Abstract][Full Text] [Related]
14. Influence of topical brimonidine on visual field in glaucoma.
Ruiz Lapuente C; Ruiz Lapuente A; Link B
Eur J Ophthalmol; 2001; 11 Suppl 2():S67-71. PubMed ID: 11592534
[TBL] [Abstract][Full Text] [Related]
15. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension.
Goñi FJ;
Eur J Ophthalmol; 2005; 15(5):581-90. PubMed ID: 16167288
[TBL] [Abstract][Full Text] [Related]
16. Effect of brimonidine tartrate 0.10% ophthalmic solution on pupil diameter.
Shemesh G; Moisseiev E; Lazar M; Kesler A
J Cataract Refract Surg; 2011 Mar; 37(3):486-9. PubMed ID: 21333872
[TBL] [Abstract][Full Text] [Related]
17. Brimonidine/Timolol: a viewpoint by Richard Fiscella.
Fiscella R
Drugs Aging; 2006; 23(9):762-3. PubMed ID: 17020400
[No Abstract] [Full Text] [Related]
18. Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans.
Schadlu R; Maus TL; Nau CB; Brubaker RF
Arch Ophthalmol; 1998 Nov; 116(11):1441-4. PubMed ID: 9823343
[TBL] [Abstract][Full Text] [Related]
19. Brimonidine/Timolol: a viewpoint by Francisco J. Goñi.
Goñi FJ
Drugs Aging; 2006; 23(9):762-3. PubMed ID: 17020402
[No Abstract] [Full Text] [Related]
20. Selectivity of site of action and systemic effects of topical alpha agonists.
Robin AL; Burnstein Y
Curr Opin Ophthalmol; 1998 Apr; 9(2):30-3. PubMed ID: 10180510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
